Selection of neoadjuvant treatment based on the 21-GENE
test results in luminal breast cancer
by Serafin Morales Murillo, Ariadna Gasol Cudos, Joel Veas
Rodriguez, Carles Canosa Morales, Jordi Melé Olivé, Felip Vilardell Villellas,
Douglas Rene Sanchez Guzman, Edelmiro Iglesias Martínez, Antonieta Salud Salvia
The Breast: January
15, 2021
Neoadjuvant chemotherapy (NAC) is an optimal option in early
breast cancer, but in ER-positive/HER2-negative (luminal) is still
controversial, although a survival benefit has recently been observed when a
histological response by Symmans’ method type 0 or I is achieved. The 21-gene
Oncotype DX Breast Recurrence Score® assay (Oncotype DX®) is a validated test
to assess the survival benefit of adjuvant chemotherapy in these patients but
its role in the neoadjuvant setting is less established. We analyzed the
results of the Oncotype DX® test in a cohort of 122 consecutive patients
selected to receive NAC based on classical clinicopathological parameters and
the correlation between the Oncotype DX® results and the pathological response
assessed by Symmans’ method.Median age was 56.5 (range 31–84) years.
